Peptides are becoming increasingly more popular in Anti-Aging and Integrative Medicine, with therapy yielding significant benefits. Part of the excitement and growth around this therapy comes from our ability to tailor to individual needs, including target-specific conditions and symptoms.
With the potential to rewrite bodily chemistry relationships and generate a restorative trend and homeostasis, peptides represent one of the pillars in the future of healthcare: applied to the treatment of injuries, combating illness, and enhancing peak performance.
Specific peptides can act as anti-oxidants, lengthen telomeres, reduce lipid oxidation, normalize cholesterol and uric acid levels, stimulate collagen and skin cell repair, and so much more.
To take it a step further, peptides combined with stem cell therapy become a potent combination directing the capability to regenerate and restore.
Peptide therapy starts with a consult and recommendations in the office, and then patients continue the therapy at home. Returning for follow-up every 3-6 months. Peptides can be part of your strategies to assist with conditions such as:
BPC-157
Pentadecapeptide BPC-157, composed of 15 amino acids, is a partial sequence of body protection compound (BPC) that is discovered in and isolated from human gastric juice. Experimentally it has between demonstrated to accelerate the healing of many different wounds, including tendon-to-bone healing and superior healing of damaged ligaments. In addition, BPC 157 seems to protect organs of the body and decrease pain in damaged areas. It can also help aid skin burns to heal at a faster rate and increase blood flow to damaged tissues. BPC-157 acts systemically in the digestive tract to combat leaky gut, IBS, Crohn’s disease, and prevent stomach ulcers. Those who suffer from discomfort due to muscle sprains, tears and damage may also benefit from treatment with this peptide.
CJC-1295 + Ipamorelin
CJC 1295 stimulates growth hormone release via binding to the pituitary. Clinical results include fat loss, increased lean muscle mass, better lipid profiles, better deep wave sleep and increased repair and recovery. Ipamorelin is a selective GH-Secretagogue and ghrelin receptor agonist with less appetite stimulation properties. Used in combination with Ipamorelin, the CJC is one of the most widely prescribed products.
Protocol
Content & Potency: 2000mcg/ml subcutaneous injection provided in a 2ml bial.
Suggested dosage: Infect 0.10ml subcutaneously 5 our of 7 nights of the week before bedtime on an empty stomach.
Using CJC 1295 in combination with Ipamorelin provide a synergistic effect, generating five times the benefits of using the CJC 1295 or Ipamorelin alone.
Clinical Research
After a single injection of CJC 1295, there were a dose dependent increases in mean plasma GH concentrations by 2- to 10-fold for 6 days or more and in mean plasma IGF-I concentrations by 1.5- to 3-fold for 9-11 days. The estimated half-life of CJC 1295 was 5.8 – 8.1 days. After multiple CJC 1295 doses, mean IGF-I levels remained above baseline for up to 28 days. No serious adverse reactions were reported. Ipadmorelin induces the release of GH at all dose levels with the concentration (SC50) required for half-maximal GH stimulation of 214 nmol/L and a meximal GH production rate of 694 mlU/L/h. The proposed PK/PD model provides a useful characterization of ipamorelin disposition and GH responses across a range of doses.
Ipamorelin
Ipamorelin is a selective GH-Secretagogue and ghrelin receptor agonist. ¬e potency of ghrelin stimulation can be compared to GHRP6 with less appetite stimulation properties. However, unlike other GH-Secretagogues this pentapeptide doesn’t release the same volumes of cortisol, acetylcholine, prolactin and aldosterone. It is for this reason Ipamorelin has been considered the rst selective GH Secretagogue.
Melanotan II
Melanotan I and Melanotan II are both analogs of the peptide hormone alphamelanocyte stimulating hormone (α-MSH) that induces skin tanning. Like its predecessor, Melanotan I, MT 2 plays a role in stimulating melanogenesis and thus provides a protective mechanism against UV rays since under its actions melanocytes are able to increase production and secretion of the hormone melanin. Scientists have also noticed that MT 2 had a positive effect on libido due to its aphrodisiac properties. Additionally, MT 2 exhibits a mild positive fat-mobilizing effect. Melanotan I is an FDA approved drug under the brand name Scenesse. Scenesse is most commonly used to treat patients that have an intolerance to light.
PROTOCOL Content & Potency:
2000mcg/ml subcutaneous injection provided in a 5ml vial.
Suggested dosage: Inject 0.1 once daily for 1 week then 0.1ml-0.2ml twice weekly for maintenance until otherwise directed by your provider. For CIRS: Inject 100mcg every other day until otherwise directed by your provider.
For CIRS: Inject 0.05ml every other day for 20 days.
PT-141
Bremelanotide (PT-141) was developed from the peptide hormone Melanotan II. In initial testing, Melanotan II induced darkening of skin pigment, but additionally caused sexual arousal and spontaneous erections as unexpected side effects in nine out of the ten original male volunteer test subjects. Further testing in animals showed Bremelanotide to induce lordosis (a sexual mating behavior) and subsequently tested for its effect in humans. Although, most of the research has been targeted to women with female sexual dysfunction, it is an effective medication in treating sexual dysfunction in both men (erectile dysfunction or impotence) and women (sexual arousal disorder). Unlike Viagra and other related medications, it does not act upon the vascular system, but directly increases sexual desire via the nervous system.
It is estimated that 43% of women (30 million is the US) suffer from sexual dysfunction and 30 million men suffer from ED, with incidence increasing 2-3-fold between ages 40-70. Bremelanotide currently has no contraindications and is 80% effective in people who don’t respond to Viagra or Cialis.
Tesamorelin
Tesamorelin is a growth hormone releasing hormone analog that increases IGF-1 levels in men and women, by an average of 181 micrograms/liters. It binds to and stimulates GHRH receptors with similar potency as endogenous GHRH. It has a host of other benefits including nootropic effects and reducing triglycerides.
Tesamorelin has subsequently been shown to decrease carotid intima-media thickness (cIMT), visceral adipose tissue (VAT), and c-reactive protein (CRP). It has not been linked to significantly affect other pituitary hormones and their respective mechanisms in the body. Additionally, it can improve cognitive
function for healthy seniors and patients with an increased risk of Alzheimer’s disease, due to mild cognitive impairment.
Thymosin
Thymosin α-1 is (TA-1) responsible for restoring immune function, particularly cell mediated immune function. Recent studies showed that the TA-1 molecule increased major histocompatibility complex (MHC) class-1 and Toll-like receptor expression as well as cytokine production, suggesting its immunoregulatory role. The drug is in Phase III trials for the treatment of hepatitis C and in Phase II trials for hepatitis B. Physicians are also using thymosin for chronic fatigue, and Lyme disease, cancer, viral diseases and an anti-aging peptide as well. TA 1 is thought to modulate the immune system by augmenting T-cell function. TA1 may affect thymocytes by stimulating their differentiation or by converting them to active T cells. TA1 is rapidly absorbed, achieving peak serum concentrations within two hours. Blood levels return to baseline within 24 hours, and the serum half-life is approximately 2 hours.
